
1. antimicrob agents chemother. 2012 feb;56(2):863-8. doi: 10.1128/aac.05284-11.
epub 2011 nov 28.

reduced impact pyrimethamine drug pressure plasmodium malariae
dihydrofolate reductase gene.

khim n(1), kim s, bouchier c, tichit m, ariey f, fandeur t, chim p, ke s, sum s, 
man s, ratsimbasoa a, durand r, ménard d.

author information: 
(1)unité d'epidémiologie moléculaire du paludisme, institut pasteur du cambodge, 
phnom penh, cambodia.

molecular investigations performed following emergence of
sulfadoxine-pyrimethamine (sp) resistance plasmodium falciparum allowed
the identification dihydrofolate reductase (dhfr) enzyme target 
pyrimethamine. although clinical cases plasmodium malariae usually
treated antifolate therapy, incorrect diagnosis high frequency of
undetected mixed infections probably exposed non-p. falciparum parasites to
antifolate therapy many areas. context, aimed assess the
worldwide genetic diversity p. malariae dhfr gene 123 samples collected
in africa asia, areas different histories sp use. among 10
polymorphic sites found, observed 7 new mutations (k55e, s58r, s59a,
f168s, n194s, d207g, t221a), led us describe 6 new dhfr proteins.
all isolates african countries classified wild type, new
mutations haplotypes recognized exclusive madagascar (except for
the double mutations nucleotides 341 342 [s114n] found one cambodian
isolate). among nonsynonymous mutations, two likely related to
pyrimethamine resistance: s58r (corresponding c59r p. falciparum s58r
in plasmodium vivax; observed one malagasy sample) s114n (corresponding to
s108n p. falciparum s117n p. vivax; observed three cambodian
samples).

doi: 10.1128/aac.05284-11 
pmcid: pmc3264216
pmid: 22123682  [indexed medline]

